Glaxosmi. Pharma

how big is Glaxosmi. Pharma?

As of Jun 06, Glaxosmithkline Pharmaceuticals Ltd has a market capitalization of 58,492.52 Cr, with recent net sales of 3749.21 Cr and a net profit of 927.58 Cr. Shareholder's funds are 1,777.64 Cr, and total assets amount to 3,410.31 Cr.

Market Cap: <BR>As of Jun 06, Glaxosmithkline Pharmaceuticals Ltd has a market capitalization of 58,492.52 Cr, categorizing it as a Large Cap company.<BR><BR>Recent Quarterly Performance: <BR>For the latest 4 quarters, the company reported Net Sales of 3749.21 Cr and a Net Profit of 927.58 Cr. This data is on a Consolidated basis.<BR><BR>Balance Sheet Snapshot: <BR>The Balance Sheet data is also on a Consolidated basis for the latest annual period ending in Mar'24. Shareholder's Funds are reported at 1,777.64 Cr, and Total Assets amount to 3,410.31 Cr.

Who are in the management team of Glaxosmi. Pharma?

As of March 2022, the management team of Glaxosmi. Pharma includes Renu S Karnad (Chairperson), Bhushan Akshikar (Managing Director), and several independent directors, among others, overseeing the company's governance and operations.

As of March 2022, the management team of Glaxosmi. Pharma includes the following individuals:<BR><BR>1. D Sundaram - Independent Director<BR>2. A A Nadkarni - Company Secretary & Compliance Officer<BR>3. P V Bhide - Independent Director<BR>4. A N Roy - Independent Director<BR>5. Subesh Williams - Director<BR>6. Renu S Karnad - Chairperson<BR>7. Sunita Maheshwari - Independent Director<BR>8. Manu Anand - Independent Director<BR>9. Bhushan Akshikar - Managing Director<BR>10. J. Chandy - Whole Time Director & CFO<BR><BR>These members play various roles in the governance and management of the company.

What does Glaxosmi. Pharma do?

GlaxoSmithKline Pharmaceuticals Limited, a subsidiary of GSK Plc., operates in the Pharmaceuticals & Biotechnology sector, reporting net sales of 974 Cr and a net profit of 263 Cr for March 2025, with a market cap of Rs 58,585 Cr. Key metrics include a P/E ratio of 63.00 and a return on equity of 47.36%.

Overview:<BR>GlaxoSmithKline Pharmaceuticals Limited is a subsidiary of UK-based GSK Plc., operating in the Pharmaceuticals & Biotechnology industry and classified as a Large Cap company.<BR><BR>History:<BR>The company is incorporated as a subsidiary of GSK Plc. and is headquartered in Mumbai. The latest quarterly results reported are for March 2025, showing net sales and profit figures.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 974 Cr (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 263 Cr (Quarterly Results - Mar 2025) <BR>Market-cap value: Rs 58,585 Cr (Large Cap)<BR><BR>Key Metrics:<BR>P/E: 63.00 <BR>Industry P/E: 35 <BR>Dividend Yield: 0.35% <BR>Debt-Equity: -1.29 <BR>Return on Equity: 47.36% <BR>Price to Book: 30.01 <BR><BR>Contact Details:<BR>Address: GSK House, Dr Annie Besant Road Worli Mumbai Maharashtra : 400030 <BR>Tel: 91-022-24959595 <BR>Email: askus@gsk.com <BR>Website: http://www.gsk-india.com

When is the next results date for Glaxosmi. Pharma?

No Upcoming Board Meetings

What is the bonus history of the Glaxosmi. Pharma?

Glaxosmithkline Pharmaceuticals Ltd issued a 1:1 bonus share on September 11, 2018, with a record date of September 13, 2018, meaning shareholders received one additional share for each share held.

Glaxosmi. Pharma, officially known as Glaxosmithkline Pharmaceuticals Ltd, has a notable bonus history. The most recent bonus issue was a 1:1 bonus, which was announced with an ex-date of September 11, 2018. The record date for this bonus was September 13, 2018. This means that shareholders received one additional share for every share they held as of the record date. If you have any more questions about the company or its financials, feel free to ask!

Has Glaxosmi. Pharma declared dividend?

Yes, Glaxosmithkline Pharmaceuticals Ltd has declared a dividend of 420%, with an ex-date of May 30, 2025. The company has shown strong price performance over various periods, with total returns ranging from 39.15% to 161.19% in the last five years.

Glaxosmithkline Pharmaceuticals Ltd has declared a dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 420%<BR>- Ex-date: 30 May 25<BR><BR>Dividend Yield: 0.35%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was 46.19%, with no dividend return, resulting in a total return of 46.19%.<BR><BR>Over the past year, the price return was 38.7%, with a dividend return of 0.45%, leading to a total return of 39.15%.<BR><BR>In the 2-year period, the price return was 147.26%, with a dividend return of 5.37%, culminating in a total return of 152.63%.<BR><BR>For the 3-year period, the price return was 127.41%, with a dividend return of 9.03%, resulting in a total return of 136.44%.<BR><BR>In the last 4 years, the price return was 127.47%, with a dividend return of 10.87%, leading to a total return of 138.34%.<BR><BR>Over the past 5 years, the price return was 148.51%, with a dividend return of 12.68%, resulting in a total return of 161.19%.<BR><BR>Overall, Glaxosmithkline Pharmaceuticals Ltd has declared a significant dividend, and the total returns over various periods indicate strong price performance, particularly in the longer term, despite relatively modest dividend returns.

Who are the peers of the Glaxosmi. Pharma?

Glaxosmi. Pharma's peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, Glenmark Pharma, Biocon, Ipca Labs, Laurus Labs, and Ajanta Pharma. Glaxosmi. Pharma has below-average growth and a 1-year return of 32.06%, higher than Cipla's 0.86%.

Peers: The peers of Glaxosmi. Pharma are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Glenmark Pharma, Biocon, Ipca Labs, Laurus Labs, and Ajanta Pharma.<BR><BR>Quality Snapshot: Excellent management risk is observed at Glaxosmi. Pharma, Dr Reddy's Labs, and Ajanta Pharma, while Good management risk is found at Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, and Ipca Labs. Average management risk is noted at Glenmark Pharma and Biocon. Growth is Excellent for Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, while Below Average growth is seen at Glaxosmi. Pharma, Divi's Lab., Torrent Pharma, Glenmark Pharma, Biocon, and Ajanta Pharma. Average growth is observed at Ipca Labs and Laurus Labs. Capital Structure is Excellent for Sun Pharma.Inds., Cipla, Dr Reddy's Labs, Glaxosmi. Pharma, and Ipca Labs, while Good capital structure is noted at Torrent Pharma and Glenmark Pharma, and Below Average at Biocon.<BR><BR>Return Snapshot: Divi's Lab. has the highest 1-year return at 51.96%, while Cipla has the lowest at 0.86%. Glaxosmi. Pharma's 1-year return of 32.06% is significantly higher than Cipla's. Additionally, Biocon and Ajanta Pharma have negative six-month returns.

Is Glaxosmi. Pharma overvalued or undervalued?

As of November 16, 2023, Glaxosmi. Pharma is considered very expensive and overvalued with a PE ratio of 62.68, significantly higher than its peers, despite a strong ROE of 47.36% and a year-to-date return of 53.11%.

As of 16 November 2023, Glaxosmi. Pharma's valuation grade has moved from expensive to very expensive, indicating a significant increase in perceived valuation. The company is currently considered overvalued. Key ratios include a PE ratio of 62.68, an EV to EBITDA ratio of 47.07, and a Price to Book Value of 29.69, all of which are substantially higher than industry norms.<BR><BR>In comparison to its peers, Glaxosmi. Pharma's PE ratio is notably higher than Sun Pharma's 35.25 and Cipla's 22.99, which are categorized as expensive and attractive, respectively. Additionally, the company's ROE stands at a remarkable 47.36%, yet this is overshadowed by its very high valuation metrics. Despite outperforming the Sensex with a year-to-date return of 53.11% compared to the Sensex's 5.63%, the elevated valuation ratios suggest that the stock may not be a prudent investment at this time.

Who are the top shareholders of the Glaxosmi. Pharma?

The top shareholders of Glaxosmi. Pharma include Glaxo Group Limited with 35.99%, various promoters, mutual funds holding 5.17%, and 255 foreign institutional investors owning 4.52%. Individual investors account for 10.6% of the shares, indicating a significant concentration of ownership among promoters.

The top shareholders of Glaxosmi. Pharma include the following:<BR><BR>1. **Glaxo Group Limited** - This entity is the largest shareholder, holding 35.99% of the company's shares.<BR>2. **Promoters** - They collectively hold the majority of the shares, although specific percentages beyond Glaxo Group Limited are not detailed.<BR>3. **Mutual Funds** - A total of 36 mutual fund schemes hold 5.17% of the shares.<BR>4. **Foreign Institutional Investors (FIIs)** - 255 FIIs collectively own 4.52% of the company.<BR>5. **SBI Nifty Midcap 150 Index Fund** - This is the highest public shareholder, holding 1.27%.<BR>6. **Individual Investors** - They account for 10.6% of the shareholding.<BR><BR>This distribution highlights a significant concentration of ownership among the promoters, particularly Glaxo Group Limited.

Is Glaxosmi. Pharma technically bullish or bearish?

As of October 30, 2025, Glaxosmi Pharma's technical trend has shifted to a bearish stance, driven by bearish MACD, Bollinger Bands, moving averages, and KST indicators, despite a mildly bearish weekly outlook from Dow Theory.

As of 30 October 2025, the technical trend has changed from mildly bearish to bearish. The current stance is bearish with moderate strength. Key indicators driving this include a bearish MACD on the weekly chart, bearish Bollinger Bands on both weekly and monthly time frames, and bearish moving averages on the daily chart. The KST is also bearish on the weekly, contributing to the overall bearish sentiment. Although the Dow Theory shows a mildly bearish weekly outlook and a bullish monthly perspective, the prevailing bearish indicators suggest a negative short-term trend for Glaxosmi. Pharma.

How has been the historical performance of Glaxosmi. Pharma?

Glaxosmi. Pharma has shown consistent growth in net sales and profitability from March 2019 to March 2025, with net sales increasing from 3,128.12 crore to 3,749.21 crore and profit after tax rising from 445.39 crore to 927.58 crore. The company's operating profit margin improved significantly, reflecting enhanced operational efficiency.

Answer:<BR>The historical performance of Glaxosmi. Pharma shows a consistent growth trend in net sales and profitability over the years leading up to March 2025.<BR><BR>Breakdown:<BR>Glaxosmi. Pharma's net sales have increased from 3,128.12 crore in March 2019 to 3,749.21 crore in March 2025, reflecting a steady upward trajectory. The total operating income followed a similar pattern, rising from 3,128.12 crore in March 2019 to 3,749.21 crore in March 2025. The company's operating profit (PBDIT) has also seen significant growth, climbing from 703.11 crore in March 2019 to 1,323.29 crore in March 2025, with an operating profit margin that improved from 19.21% to 31.4% over the same period. Profit before tax surged from 682.66 crore in March 2019 to 1,259.88 crore in March 2025, while profit after tax reached 927.58 crore in March 2025, up from 445.39 crore in March 2019. The earnings per share (EPS) increased notably from 26.29 in March 2019 to 54.75 in March 2025. On the balance sheet, total assets grew from 3,025.05 crore in March 2020 to 3,967.20 crore in March 2025, while total liabilities increased from 3,025.05 crore to 3,967.20 crore during the same period. The cash flow from operating activities improved significantly, reaching 1,289 crore in March 2025 compared to 490 crore in March 2020, indicating enhanced operational efficiency and cash generation capabilities.

Are Glaxosmi. Pharma latest results good or bad?

GlaxoSmithKline Pharmaceuticals' latest results show a net profit increase of 25.60% quarter-on-quarter, but a 3.05% year-on-year revenue decline raises concerns about long-term sustainability. While profit margins are strong, the negative revenue trend suggests underlying challenges.

GlaxoSmithKline Pharmaceuticals' latest results present a mixed picture. On one hand, the company reported a net profit of ₹257.49 crore for Q2 FY26, which reflects a healthy increase of 25.60% quarter-on-quarter and a modest growth of 1.98% year-on-year. This indicates strong operational efficiency, particularly with an operating margin that has reached 34.26%, the highest in eight quarters.<BR><BR>However, the revenue story is less favorable. The company experienced a year-on-year decline in revenue of 3.05%, totaling ₹979.94 crore. This marks the second consecutive quarter of negative revenue growth, raising concerns about the sustainability of profit growth driven primarily by margin expansion rather than sales increases.<BR><BR>Overall, while the profit margins and operational efficiency are commendable, the stagnation in revenue growth suggests underlying challenges that could impact long-term performance. Investors may need to weigh the strong profit figures against the concerning revenue trends when assessing the company's overall health.

Should I buy, sell or hold Glaxosmi. Pharma?

Why is Glaxosmithkline Pharmaceuticals Ltd falling/rising?

As of 02-Feb, Glaxosmithkline Pharmaceuticals Ltd's stock price is at 2,394.30, down 0.55% after a trend reversal. Despite a strong annual return of 22.39%, concerns over long-term growth, high valuation, and recent flat results are contributing to the current decline.

As of 02-Feb, Glaxosmithkline Pharmaceuticals Ltd's stock price is falling, currently at 2,394.30, reflecting a decrease of 13.25 points or 0.55%. This decline follows a trend reversal after two consecutive days of gains. The stock has underperformed its sector by 0.48% today and reached an intraday low of Rs 2,345, which is a 2.6% drop from its previous price.<BR><BR>Despite a strong performance over the past year, with a return of 22.39% compared to the market's 5.37%, the stock faces challenges that contribute to its current decline. The company's long-term growth appears poor, with net sales growing at an annual rate of only 3.77% over the last five years. Additionally, the stock is considered expensive, trading at a price-to-book value of 23.8, which is a premium compared to its peers. The recent flat results reported in September, along with a low debtors turnover ratio of 1.11 times, further indicate underlying issues.<BR><BR>While there has been rising investor participation, as evidenced by a 52.27% increase in delivery volume on January 30, the overall sentiment appears to be affected by concerns over the company's growth prospects and valuation, leading to the current decline in stock price.

Which are the latest news on Glaxosmi. Pharma?